The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1
作者：
Chen, Xi [1 ]
Wei, Xinyu [1 ]
Yao, Peizhuo [1 ]
Liu, Yanbin [1 ]
Guan, Haitao [2 ]
Kang, Huafeng [2 ]
Liu, Di [2 ]
Diao, Yan [2 ]
Ma, Xiaobin [2 ]
Min, Weili [2 ]
Shan, Changyou [2 ]
Zhao, Yang [2 ]
Zhao, Fang [2 ]
Chen, Yuanyuan [3 ]
Xiao, Dong [4 ]
She, Qing [3 ]
Liu, Youhuai [3 ]
Zhang, Yinbin [2 ]
Zhang, Shuqun [2 ]
机构：
[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China
[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China
来源：
CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期
关键词：
1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;
D O I：
10.1016/j.clbc.2024.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 202
页数：8
相关论文
共 34 条
  • [1] Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
    Ayoub, Nehad M.
    Jaradat, Sara K.
    Al-Shami, Kamal M.
    Alkhalifa, Amer E.
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Brufsky, Adam M.
    Hurvitz, Sara
    Perez, Edith
    Swamy, Raji
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4286 - 4293
  • [3] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
    Burstein, H. J.
    Curigliano, G.
    Loibl, S.
    Dubsky, P.
    Gnant, M.
    Poortmans, P.
    Colleoni, M.
    Denkert, C.
    Piccart-Gebhart, M.
    Regan, M.
    Senn, H. -J.
    Winer, E. P.
    Thurlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1541 - 1557
  • [4] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Cardoso, F.
    Kyriakides, S.
    Ohno, S.
    Penault-Llorca, F.
    Poortmans, P.
    Rubio, I. T.
    Zackrisson, S.
    Senkus, E.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1194 - 1220
  • [5] Docetaxel combined with targeted therapies in metastatic breast cancer
    Cortes, Javier
    Roche, Henri
    [J]. CANCER TREATMENT REVIEWS, 2012, 38 (05) : 387 - 396
  • [6] Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
    Erdem, Lale
    Giovannetti, Elisa
    Leon, Leticia G.
    Honeywell, Richard
    Peters, Godefridus J.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (15) : 1649 - 1659
  • [7] Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
    Gacche, Rajesh N.
    Meshram, Rohan J.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1846 (01): : 161 - 179
  • [8] Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
    Garcia, Josep
    Hurwitz, Herbert, I
    Sandler, Alan B.
    Miles, David
    Coleman, Robert L.
    Deurloo, Regula
    Chinot, Olivier L.
    [J]. CANCER TREATMENT REVIEWS, 2020, 86
  • [9] Breast Cancer, Version 3.2020
    Gradishar, William J.
    Anderson, Benjamin O.
    Abraham, Jame
    Aft, Rebecca
    Agnese, Doreen
    Allison, Kimberly H.
    Blair, Sarah L.
    Burstein, Harold J.
    Dang, Chau
    Elias, Anthony D.
    Giordano, Sharon H.
    Goetz, Matthew P.
    Goldstein, Lori J.
    Isakoff, Steven J.
    Krishnamurthy, Jairam
    Lyons, Janice
    Marcom, P. Kelly
    Matro, Jennifer
    Mayer, Ingrid A.
    Moran, Meena S.
    Mortimer, Joanne
    O'Regan, Ruth M.
    Patel, Sameer A.
    Pierce, Lori J.
    Rugo, Hope S.
    Sitapati, Amy
    Smith, Karen Lisa
    Smith, Mary Lou
    Soliman, Hatem
    Stringer-Reasor, Erica M.
    Telli, Melinda L.
    Ward, John H.
    Young, Jessica S.
    Burns, Jennifer L.
    Kumar, Rashmi
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 452 - 478
  • [10] Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]
1234